Regado's REG1 gets Fast Track designation

|By:, SA News Editor

FDA designates Regado Biosciences' (RGDO) REG1 for anticoagulant therapy for use in patients with coronary artery disease during percutaneous coronary interventions (PCI) a Fast Track development program.

The product is currently in a Phase 3 clinical trial.

Five analysts rate the company at least a Buy.